Cargando…
Assessing factors influencing communities’ acceptability of mass drug administration for the elimination of lymphatic filariasis in Guyana
BACKGROUND: Guyana is one of four countries in the Latin American Region where lymphatic filariasis (LF) remains endemic. In preparation for the introduction of a new triple drug therapy regimen (ivermectin, diethylcarbamazine, and albendazole (IDA)) in 2019, an acceptability study was embedded with...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452018/ https://www.ncbi.nlm.nih.gov/pubmed/34543269 http://dx.doi.org/10.1371/journal.pntd.0009596 |
_version_ | 1784569977730236416 |
---|---|
author | Niles, Reza A. Thickstun, Charles R. Cox, Horace Dilliott, Daniel Burgert-Brucker, Clara R. Harding-Esch, Emma M. Clementson, Nikita Sampson, Annastacia Alexandre, Jean Seme Morice Trejos, Ana C. Scholte, Ronaldo G. Carvalho Krentel, Alison |
author_facet | Niles, Reza A. Thickstun, Charles R. Cox, Horace Dilliott, Daniel Burgert-Brucker, Clara R. Harding-Esch, Emma M. Clementson, Nikita Sampson, Annastacia Alexandre, Jean Seme Morice Trejos, Ana C. Scholte, Ronaldo G. Carvalho Krentel, Alison |
author_sort | Niles, Reza A. |
collection | PubMed |
description | BACKGROUND: Guyana is one of four countries in the Latin American Region where lymphatic filariasis (LF) remains endemic. In preparation for the introduction of a new triple drug therapy regimen (ivermectin, diethylcarbamazine, and albendazole (IDA)) in 2019, an acceptability study was embedded within sentinel site mapping in four regions to assess mass drug administration (MDA) coverage and compliance, acceptability, and perceptions about treatment and disease. The results from this survey would inform the rollout of IDA in Guyana in 2019. METHODS: Data collection for the study occurred in August 2019, using a validated questionnaire administered by trained enumerators. Across all regions, a total of 1,248 participants were sampled by the Filarial Mapping team. Four-hundred and fifty-one participants aged over 18 years were randomly selected for participation in an expanded acceptability questionnaire. All data were captured in Secure Data Kit (SDK). RESULTS: Acceptability was measured using a mean acceptability score. Unadjusted mean scores ranged from 24.6 to 29.3, with 22.5 as the threshold of acceptability. Regional variation occurred across many indicators of interest: self-rated understanding about LF, mechanisms of LF transmission, LF drug safety and history of treatment during MDA. Region IV (Georgetown) recorded higher knowledge about LF, but lower compliance and acceptability. Number of pills was not perceived as a concern. CONCLUSION: Acceptability of MDA was good across all four regions under study. Results from this study set a baseline level for key indicators and acceptability, from which the acceptability of IDA can be measured. Regional variations across indicators suggest that localized approaches should be considered for social mobilization and MDA delivery to capture these contextual differences. |
format | Online Article Text |
id | pubmed-8452018 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-84520182021-09-21 Assessing factors influencing communities’ acceptability of mass drug administration for the elimination of lymphatic filariasis in Guyana Niles, Reza A. Thickstun, Charles R. Cox, Horace Dilliott, Daniel Burgert-Brucker, Clara R. Harding-Esch, Emma M. Clementson, Nikita Sampson, Annastacia Alexandre, Jean Seme Morice Trejos, Ana C. Scholte, Ronaldo G. Carvalho Krentel, Alison PLoS Negl Trop Dis Research Article BACKGROUND: Guyana is one of four countries in the Latin American Region where lymphatic filariasis (LF) remains endemic. In preparation for the introduction of a new triple drug therapy regimen (ivermectin, diethylcarbamazine, and albendazole (IDA)) in 2019, an acceptability study was embedded within sentinel site mapping in four regions to assess mass drug administration (MDA) coverage and compliance, acceptability, and perceptions about treatment and disease. The results from this survey would inform the rollout of IDA in Guyana in 2019. METHODS: Data collection for the study occurred in August 2019, using a validated questionnaire administered by trained enumerators. Across all regions, a total of 1,248 participants were sampled by the Filarial Mapping team. Four-hundred and fifty-one participants aged over 18 years were randomly selected for participation in an expanded acceptability questionnaire. All data were captured in Secure Data Kit (SDK). RESULTS: Acceptability was measured using a mean acceptability score. Unadjusted mean scores ranged from 24.6 to 29.3, with 22.5 as the threshold of acceptability. Regional variation occurred across many indicators of interest: self-rated understanding about LF, mechanisms of LF transmission, LF drug safety and history of treatment during MDA. Region IV (Georgetown) recorded higher knowledge about LF, but lower compliance and acceptability. Number of pills was not perceived as a concern. CONCLUSION: Acceptability of MDA was good across all four regions under study. Results from this study set a baseline level for key indicators and acceptability, from which the acceptability of IDA can be measured. Regional variations across indicators suggest that localized approaches should be considered for social mobilization and MDA delivery to capture these contextual differences. Public Library of Science 2021-09-20 /pmc/articles/PMC8452018/ /pubmed/34543269 http://dx.doi.org/10.1371/journal.pntd.0009596 Text en © 2021 Niles et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Niles, Reza A. Thickstun, Charles R. Cox, Horace Dilliott, Daniel Burgert-Brucker, Clara R. Harding-Esch, Emma M. Clementson, Nikita Sampson, Annastacia Alexandre, Jean Seme Morice Trejos, Ana C. Scholte, Ronaldo G. Carvalho Krentel, Alison Assessing factors influencing communities’ acceptability of mass drug administration for the elimination of lymphatic filariasis in Guyana |
title | Assessing factors influencing communities’ acceptability of mass drug administration for the elimination of lymphatic filariasis in Guyana |
title_full | Assessing factors influencing communities’ acceptability of mass drug administration for the elimination of lymphatic filariasis in Guyana |
title_fullStr | Assessing factors influencing communities’ acceptability of mass drug administration for the elimination of lymphatic filariasis in Guyana |
title_full_unstemmed | Assessing factors influencing communities’ acceptability of mass drug administration for the elimination of lymphatic filariasis in Guyana |
title_short | Assessing factors influencing communities’ acceptability of mass drug administration for the elimination of lymphatic filariasis in Guyana |
title_sort | assessing factors influencing communities’ acceptability of mass drug administration for the elimination of lymphatic filariasis in guyana |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452018/ https://www.ncbi.nlm.nih.gov/pubmed/34543269 http://dx.doi.org/10.1371/journal.pntd.0009596 |
work_keys_str_mv | AT nilesrezaa assessingfactorsinfluencingcommunitiesacceptabilityofmassdrugadministrationfortheeliminationoflymphaticfilariasisinguyana AT thickstuncharlesr assessingfactorsinfluencingcommunitiesacceptabilityofmassdrugadministrationfortheeliminationoflymphaticfilariasisinguyana AT coxhorace assessingfactorsinfluencingcommunitiesacceptabilityofmassdrugadministrationfortheeliminationoflymphaticfilariasisinguyana AT dilliottdaniel assessingfactorsinfluencingcommunitiesacceptabilityofmassdrugadministrationfortheeliminationoflymphaticfilariasisinguyana AT burgertbruckerclarar assessingfactorsinfluencingcommunitiesacceptabilityofmassdrugadministrationfortheeliminationoflymphaticfilariasisinguyana AT hardingeschemmam assessingfactorsinfluencingcommunitiesacceptabilityofmassdrugadministrationfortheeliminationoflymphaticfilariasisinguyana AT clementsonnikita assessingfactorsinfluencingcommunitiesacceptabilityofmassdrugadministrationfortheeliminationoflymphaticfilariasisinguyana AT sampsonannastacia assessingfactorsinfluencingcommunitiesacceptabilityofmassdrugadministrationfortheeliminationoflymphaticfilariasisinguyana AT alexandrejeanseme assessingfactorsinfluencingcommunitiesacceptabilityofmassdrugadministrationfortheeliminationoflymphaticfilariasisinguyana AT moricetrejosanac assessingfactorsinfluencingcommunitiesacceptabilityofmassdrugadministrationfortheeliminationoflymphaticfilariasisinguyana AT scholteronaldogcarvalho assessingfactorsinfluencingcommunitiesacceptabilityofmassdrugadministrationfortheeliminationoflymphaticfilariasisinguyana AT krentelalison assessingfactorsinfluencingcommunitiesacceptabilityofmassdrugadministrationfortheeliminationoflymphaticfilariasisinguyana |